IL2RA and acute myeloid leukemia: Because molecular insights have not become manifested in a routine clinical practice, and are not available for all patients, we recommend that IL-2Rα testing, which is cost-effective and less time-consuming, be combined with cytogenetic risk evaluation and that IL-2Rα+ intermediate-risk patients are assigned to an adverse-risk group to improve AML prognostication in a shorter time (Fig 5B).